2024-510761-42-00招募中1 期
A first-in-human study of the safety of an immunosuppressive antibody (IMP761) in healthy volunteers.
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Immutep
- 入组人数
- 79
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Principal Investigator, M. Moerland
Scientific
Immutep
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety and immunogenicity of ACT-1239 in healthy volunteersInfection - Other infectious diseasesMalariaACTRN12619001022156Artificial Cell Technologies, Inc.50
已完成
不适用
Evaluation of a prototype vaccine against enterotoxigenic Escherichia coli diarrhoeaEnterotoxigenic E. coli (ETEC) diarrhoeaInfections and InfestationsEnterotoxigenic Escherichia coli infectionISRCTN23764070Gothenburg University Vaccine Research Institute (GUVAX) (Sweden)60
进行中（未招募）
1 期
Study of increasing doses of genetically modified GD2-specific T cells in patients with metastatic melanoma and refractory solid tumoursMetastatic melanomaRefractory solid tumoursCancer - Malignant melanomaACTRN12613000198729Royal Adelaide Hospital Cancer Centre12
已完成
不适用
A safety and immunogenicity phase 1 trial with an adjuvated TB subunit vaccine (Ag85B - ESAT-6 + IC31) administered in PPD positive volunteers at 0 and 2 monthsPrevention10028440TuberculosisNL-OMON30684Statens Serum Institut20
招募中
3 期
Clinical Trial of quadrivalent Papilloguard4 vaccine (Human Papillomavirus Types 6, 11, 16, 18) manufactured by Nivad Pharmed Salamat in comparison with GardasilGenital wart prevention.Anogenital (venereal) wartsA63.0IRCT20240120060741N1ivad Pharmed Salamat670